Clinical trials: Benign Hyperplasia of Prostate
Prostatic Hyperplasia
Study to Evaluate the Symptomatic Relief Effects of FLOMAX® in Patients With Signs and Symptoms of Benign Prostatic Hyperplasia
Study to evaluate the symptomatic relief afforded by tamsulosin hydrochloride capsules in patients with signs and symptoms of benign prostatic hyperplasia (BPH).
- Trial name
- NCT02244242
- Testing
- Tamsulosin hydrochloride
- Volunteers
- 493 people
- Sponsor
- Boehringer Ingelheim
Benign Prostatic Hyperplasia
Efficacy and Safety of Combination Therapy Compared With Monotherapy in Patients With Benign Prostatic Hyperplasia
Efficacy and Safety of Combination Therapy Compared With Monotherapy in Patients With Benign Prostatic Hyperplasia
- Trial name
- NCT07870759
- Testing
- Finasteride 5 mg Tablet, single dose, Tamsulosin 0.4Mg Capsule
- Volunteers
- 660 people
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Benign Prostatic Hyperplasia
Treatment of Symptomatic BPH Patients Undergoing Anticoagulant Therapy Using the PlasmaButton Vaporization Electrode
The purpose of this observational study is to evaluate the outcomes of using the PlasmaButton electrode in the treatment on Benign Prostatic Hyperplasia (BPH) while on anticoagulation medication.
- Trial name
- NCT02019030
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Olympus Corporation of the Americas
Benign Prostatic Hyperplasia
Transperineal Intraprostatic Injection of PRX302 Under Ultrasound Guidance for Management of Prostatic Hyperplasia
The purpose of this study is to determine whether PRX302 is safe and effective in the treatment of moderate to severe Benign Prostatic Hyperplasia (BPH).
- Trial name
- TRIUMPH-1 (NCT00889707)
- Testing
- PRX302
- Where
- 9 sites in Canada
- Volunteers
- 92 people
- Sponsor
- Sophiris Bio Corp
Benign Prostatic Hyperplasia
MCS in Treating Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia
Phase III, Randomized, double-blind, parallel placebo-controlled study. Two arms: MCS (30mg/day) vs. placebo. Subproject MCS-2: alpha-blocker naïve subjects Subproject MCS-3: subjects responding poorly to alpha-blocker
- Trial name
- NCT00501371
- Testing
- MCS
- Where
- 5 sites in Taiwan
- Volunteers
- 85 people
- Sponsor
- Health Ever Bio-Tech Co., Ltd.
Benign Prostatic Hyperplasia
Dose Ranging Study of Alfuzosin in Patients With Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia
The primary objective is to assess the dose-response relationship of SL77.0499 10 (alfuzosin hydrochloride) 5 mg, 10 mg, 15 mg, and placebo once daily during a 12-week oral administration period for the efficacy in patients with…
- Trial name
- NCT00409357
- Testing
- SL77.0499-10 (alfuzosin hydrochloride)
- Where
- Japan
- Volunteers
- 473 people
- Sponsor
- Sanofi
Erectile Dysfunction, Benign Prostatic Hyperplasia
Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction
The purpose of this study is to evaluate the efficacy, dose-response and safety of udenafil 25 mg, 50 mg and 75 mg every day (q.d.) for 12 weeks in the treatment of lower urinary tract symptoms (LUTS) associated with benign…
- Trial name
- NCT01967251
- Testing
- Udenafil
- Where
- 8 sites in Mexico
- Sponsor
- Takeda
Nocturia
Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH)
This study will investigate the efficacy and safety of fedovapagon in the treatment of nocturia in men with BPH.
- Trial name
- EQUINOC (NCT02637960)
- Testing
- Fedovapagon 2 mg
- Where
- 48 sites in United States
- Volunteers
- 432 people
- Sponsor
- Vantia Ltd
Benign Prostatic Hyperplasia
Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily
The purpose of this study is to determine whether an experimental drug known as tadalafil given once daily can reduce the symptoms associated with Benign Prostatic Hyperplasia (straining, urinary frequency, feeling like your…
- Trial name
- NCT00827242
- Testing
- tadalafil
- Where
- 27 sites in United States, Argentina and 3 more
- Volunteers
- 325 people
- Sponsor
- Eli Lilly and Company
Prostatic Hyperplasia
Benign Prostatic Hyperplasia (BPH) Screening Tool Case Finding Study in Subjects >=50 Years
This non-randomized, interventional study will be conducted in a general practice setting to assess the utility of a benign prostatic enlargement (BPE)/benign prostatic obstruction (BPO) screening tool in conjunction with…
- Trial name
- NCT02757963
- Testing
- Benign prostatic enlargement (BPE)/Benign prostatic obstruction (BPO) screening tool, International Prostate Symptom Score (IPSS) screening tool
- Where
- 45 sites in France, Germany and 3 more
- Volunteers
- 1,679 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia, Enlarged Prostate
Study of the Efficacy and Safety of Lonidamine for the Treatment of Symptomatic Benign Prostatic Hyperplasia
The purpose of this study is to evaluate the efficacy of lonidamine (50mg, 150mg) compared to placebo in subjects with symptomatic BPH.
- Trial name
- NCT00435448
- Testing
- Lonidamine
- Where
- 58 sites in Germany, Hungary and 2 more
- Volunteers
- 480 people
- Sponsor
- Threshold Pharmaceuticals
Benign Prostatic Hyperplasia, Prostatic Hyperplasia
Dutasteride 0.5mg For The Treatment Of Chinese Patients With Benign Prostatic Hyperplasia (BPH)
This randomized, double-blind, placebo-controlled, six-month parallel-group study assess efficacy and safety of dutasteride 0.5mg once daily in Chinese patients with Benign Prostatic Hyperplasia (BPH) , followed by a 12-month…
- Trial name
- NCT00527605
- Testing
- Dutasteride 0.5mg capsule
- Where
- 12 sites in China
- Volunteers
- 253 people
- Sponsor
- GlaxoSmithKline
Benign Prostatic Hyperplasia
Temperature Mapping of the Prostate With the Wallterm™ System
To measure intra-prostatic temperatures and evaluate the shape and size of necrotic lesions achieved under the standard treatment protocol in men with benign prostatic hyperplasia (BPH).
- Trial name
- WT-DK-TMW08 (NCT00662350)
- Testing
- The Wallterm™ System
- Where
- Denmark
- Volunteers
- 6 people
- Sponsor
- Pnn Medical A/S
Benign Prostatic Hyperplasia
Effects of Tadalafil Once a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
The purpose of this study is to evaluate the function of the bladder and urethra during urinary storage or voiding in men with signs and symptoms of benign prostatic hyperplasia treated with either placebo or tadalafil.
- Trial name
- NCT00386009
- Testing
- Tadalafil
- Where
- 13 sites in United States, Greece and 1 more
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia Symptoms Who Are Being Treated With Alpha Blockers
The purpose of this study is to evaluate the safety and efficacy of tadalafil when given to men who are currently taking a medication called an alpha blocker for the treatment of benign prostatic hyperplasia (BPH) symptoms (such…
- Trial name
- NCT00848081
- Testing
- Tadalafil
- Where
- 31 sites in United States, Puerto Rico
- Volunteers
- 318 people
- Sponsor
- Eli Lilly and Company
Benign Prostatic Hyperplasia
Safety and Efficacy of Botulinum Toxin Type A to Treat Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
This study will evaluate the safety and efficacy of intraprostatic administration of botulinum toxin Type A (BOTOX®) compared with placebo to treat urinary tract symptoms due to benign prostatic hyperplasia.
- Trial name
- NCT01107392
- Testing
- botulinum toxin Type A, Normal saline
- Where
- 8 sites in United States, Canada and 6 more
- Volunteers
- 315 people
- Sponsor
- Allergan
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
UK Post-market Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue
A post-market, non-interventional, two-arm, long-term follow-up study of patients previously enrolled in the WATER Study (NCT02505919) - which was a prospective multi-centre randomized blinded study comparing Aquablation of the…
- Trial name
- NCT04658056
- Where
- United Kingdom
- Volunteers
- 46 people
- Sponsor
- PROCEPT BioRobotics
Benign Prostatic Hyperplasia
A Study to Investigate the Effects on Blood Pressure and Pulse Rate of a Single 100mg Dose of Sildenafil in Patients With Benign Prostatic Hyperplasia Who Are Being Treated With Doxazosin
To investigate the effects of a single dose of sildenafil (100 mg) or placebo on blood pressure and pulse rate in subjects taking doxazosin for benign prostatic hyperplasia (BPH).
- Trial name
- NCT00645034
- Testing
- sildenafil
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Acute Urinary Retention, Benign Prostate Hypertrophy(BPH)
Study of Teverelix DP on Prostate Volume, Urinary Function and Clinical Outcomes Following Acute Urinary Retention
This randomized, double-blind, placebo-controlled Phase 2 study is evaluating Teverelix DP in men following a first episode of acute urinary retention (AUR) associated with benign prostatic hyperplasia (BPH), a population at risk…
- Trial name
- NCT07733934
- Testing
- Teverelix DP
- Volunteers
- 126 people
- Sponsor
- Antev Ltd.
Benign Prostatic Hyperplasia
Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia
This is a randomized, double-blind, placebo-controlled, parallel-design, multinational, 12-week study to compare the efficacy, dose response, and safety of tadalafil once a day versus placebo in men with signs and symptoms of…
- Trial name
- NCT00384930
- Testing
- tadalafil
- Where
- United States
- Volunteers
- 1,058 people
- Sponsor
- Eli Lilly and Company